scholarly article | Q13442814 |
P2093 | author name string | Amit S Kalgutkar | |
Tristan S Maurer | |||
Phoebe Chiang | |||
Jiri Aubrecht | |||
Richard V Coelho | |||
Evan B Smith | |||
Stephanie L Coffing | |||
Chandra Vage | |||
Klaas Schildknegt | |||
Deepak K Dalvie | |||
Kim F McClure | |||
Jennifer R Cheung | |||
Victor F Soliman | |||
Mary E Lame | |||
P433 | issue | 6 | |
P921 | main subject | obesity | Q12174 |
genotoxicity | Q1009245 | ||
P304 | page(s) | 848-858 | |
P577 | publication date | 2007-03-07 | |
P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
P1476 | title | Genotoxicity of 2-(3-chlorobenzyloxy)-6-(piperazinyl)pyrazine, a novel 5-hydroxytryptamine2c receptor agonist for the treatment of obesity: role of metabolic activation | |
P478 | volume | 35 |
Q34766538 | 5-HT2C ligands: recent progress |
Q37950014 | A review of the use of in silico methods to predict the chemistry of molecular initiating events related to drug toxicity |
Q38218540 | Biotransformation and bioactivation reactions of alicyclic amines in drug molecules |
Q89993903 | Chemicals and Drugs Forming Reactive Quinone and Quinone Imine Metabolites |
Q37802740 | Deleterious Effects of Reactive Metabolites |
Q39768889 | Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel? |
Q46240693 | Evaluation of chemically diverse 5-HT₂c receptor agonists on behaviours motivated by food and nicotine and on side effect profiles |
Q85015974 | Handling reactive metabolite positives in drug discovery: What has retrospective structure–toxicity analyses taught us? |
Q56115898 | Metabolism-guided drug design |
Q36805380 | Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents |
Q44430233 | Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway |
Q91749643 | Targeting the 5-HT2C Receptor in Biological Context and the Current State of 5-HT2C Receptor Ligand Development |
Q38177342 | Toxicophores, reactive metabolites and drug safety: when is it a cause for concern? |
Q35823591 | We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders. |
Search more.